UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-A

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

MEDICENNA THERAPEUTICS CORP.

(Exact Name of Registrant as Specified In Its Charter)

Canada (State or Other Jurisdiction of Incorporation or Organization) Not applicable (I.R.S. Employer Identification No.)

2 Bloor St. W., 7th Floor, Toronto, Ontario, Canada (Address of Principal Executive Offices)

M4W 3E2 (Zip Code)

Securities to be registered pursuant to Section 12(b) of the Act:

Title of each class to be so registered	Name of each exchange on which each class is to be registered
Common Shares (no par value per share)	The Nasdaq Stock Market LLC
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), please check the following box. ⊠	
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), please check the following box. \Box	
If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. \Box	
Securities Act registration statement or Regulation A offering statement file number to which this form relates: 333-238905	
Securities to be registered pursuant to Section 12(g) of the Act: None	

INFORMATION REQUIRED IN REGISTRATION STATEMENT

Item 1. Description of Registrant's Securities to be Registered.

The securities to be registered consist of common shares, no par value ("Common Shares") of Medicenna Therapeutics Corp. (the "Registrant"). The description of the Registrant's Common Shares under the sections captioned "Description of Share Capital," "Certain Canadian Federal Income Tax Considerations," and "Certain U.S. Federal Income Tax Considerations" in the short form base shelf prospectus, which is included in the Registrant's registration statement on Form F-10 (File No. 333-238905) (the "Registration Statement") initially filed with the Securities and Exchange Commission on June 3, 2020, as subsequently amended by any amendments to such Registration Statement, is incorporated herein by reference.

Item 2. Exhibits.

Under the "Instructions as to Exhibits" section of Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are to be registered on The Nasdaq Stock Market LLC and the securities to be registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized, in the City of Toronto, Province of Ontario, Canada on August 18, 2020.

MEDICENNA THERAPEUTICS CORP.

By: /s/ Elizabeth Williams
Name: Elizabeth Williams
Title: Chief Financial Officer